Name of leader and affiliation: Laura Huopaniemi, Sanna Laakso, Mobidiag Ltd, Finland
Role in RAPP-ID:
Mobidiag is responsible for activities related to fungal detection including: selecting and designing primers and probes for the most clinically relevant fungal species in sepsis (WP2); participating in development of integrated fungal sample preparation and efficient DNA extraction methods or antigen-based capturing for the corresponding specimens, avoiding the potential environmental fungal bioburden (WP3); fungal bio-assay optimisation using mainly NA-based detection technologies validated and developed in this consortium (WP5); pre-clinical validation of developed fungal assay (WP7). In addition, MD will provide the Prove-itTM platform for validation of various pathogen and host biomarkers (WP4).
The company develops and provides unique and innovative microarray-based Prove-it™ technology for early and accurate diagnosis of life-threatening pathogenic microbes causing severe infections. The diagnostic products are based on PCR and microarray identification of microorganisms and their resistance markers, applying assay on biochip platforms, and providing associated ICT solutions.
Laura Huopaniemi, R&D Director, PhD, joined Mobidiag in 2005 and is currently responsible for companys´s Research and Development activities. Dr Huopaniemi has been involved in the development, productisation, production and commercialization of several CE-IVD status products in the field of molecular diagnostics.
Sanna Laakso, R&D Specialist, MSc. (Microbiology), joined Mobidiag 2006. Her main responsibilities in Mobidiag R&D team relate to the molecular design and development of CE-IVD marked PCR and microarray based diagnostic tests. She has experience also from the other EU funded project (InTopSens).
Antti Ojala, CEO, is responsible for financial issues.